HilleVax announced three leadership positions have been filled Monday morning.
Berger joins HilleVax from GSK’s Vaccine Therapeutic Group, where he most recently served as VP and global regulatory head. While at GSK, he led a portfolio of more than 40 vaccines. Before GSK, Berger worked at Merck in the regulatory affairs group and brings nearly 30 years of experience in regulatory strategies.
Chatterji originally joined HilleVax in January 2022, where she served as SVP of technical operations. Before that, Chatterji worked at Catalyst Biosciences, serving as SVP of biologics development and manufacturing. She’s also held roles at Exelixis, Grifols, Novartis Vaccines and Diagnostics and Bayer HealthCare.
Maltbie, meanwhile, steps into his new role from his previous position of VP of finance at HilleVax. Before HilleVax, Maltbie served as VP of finance at TScan Therapeutics as well as VP of finance at Axcella.
HilleVax is a company focused primarily on developing vaccines, and its initial lead program, HIL-214, is a virus-like particle (VLP)-based vaccine candidate for moderate-to-severe acute gastroenteritis (AGE) caused by norovirus.
HIL-214 has now been tested in some nine Phase I and II trials. It was shown to be well-tolerated with a clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis after norovirus infection, HilleVax states on its website.
In December last year, HilleVax released immunogenicity results from its ongoing NEST-IN1 Phase IIb trial for the therapy, noting the results were positive.
“We are very pleased with the immunogenicity results from the NEST-IN1 run-in cohort which were consistent with our expectations based on previous studies of HIL-214 given to infants,” HilleVax CEO Rob Hershberg said in a December statement.
He noted the company expects full NEST-IN1 topline safety and efficacy data in the second half of 2023.
“We are excited to welcome Ozzie to HilleVax and announce the promotions of Anju and Shane as we continued to progress NEST-IN1 — our Phase2b trial of HIL-214 for the prevention of moderate-to-severe norovirus-related acute gastroenteritis,” Hershberg said in a statement regarding the latest hires. “Each of these individuals is an important leader of our organization and will be critical as we work to develop HIL-214.”